Dave Lemus Promoted to CEO of Sigma-Tau Pharmaceuticals
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
GAITHERSBURG, Md., April 29, 2013 (GLOBE NEWSWIRE) -- The Board of Directors of Sigma-Tau Pharmaceuticals, Inc. today announced that Dave Lemus has been promoted to the newly created position of Chief Executive Officer, effective immediately. Mr. Lemus had served as Chief Operating Officer of the Company since March 2012, and joined the Company as Vice President of Finance in July 2011.
Commenting on today's news, Professor Trevor M. Jones CBE, President of Sigma Tau USA Inc., stated, "We are delighted to appoint Dave to the new position of Chief Executive Officer of Sigma Tau Inc. His appointment comes at a pivotal time in the development of the Company, as it now expands via commercialization of its proprietary internal R&D pipeline, and the pursuit of externally driven growth opportunities. The appointment of the Chief Executive role reflects the commitment Sigma Tau USA Inc. has to the field of rare diseases, and to the significant impact we expect these medicines will ultimately have on their respective physician and patient communities, alike."
Prior to joining Sigma-Tau Pharmaceuticals in 2011, Mr. Lemus was Executive Vice President and Chief Financial Officer of MorphoSys AG, where he launched Germany's first-ever biotechnology IPO in 1999. Before MorphoSys, Mr. Lemus held a variety of senior management positions at Hoffmann La Roche and Lindt Chocolate, in Switzerland. Mr. Lemus presently serves as Board Chairman of Proteros Gmbh in Munich, Germany, and as a Non-Executive Board Member of Toronto, Canada-based Axela Inc.
About Sigma-Tau Pharmaceuticals
Sigma-Tau Pharmaceuticals, Inc. is a U.S. based, wholly owned subsidiary of the Sigma-Tau Group, a member of the Global Rare Disease Franchise, and is dedicated to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland. Since 1989, the company's products have been focused on kidney disease, certain genetic disorders and cancers. With more than 7,000 identified rare diseases that affect approximately 30 million patients in the U.S. alone, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need. For more information about the company, visit www.sigmatau.com.
Senior Vice President
Rx Communications Group, LLC